News
Media
Peer ExchangeCase-Based Psych PerspectivesClinical Case CollectiveInsightsPeers & PerspectivesSlideshowsVideos
Conferences
Conference CoverageConference Listing
Publication
Psychiatric Times
More
Job Board
CME/CE
Partners
Editorial
Resources
Between the LinesExpert PerspectivesClinical ConsultClinical ScalesInteractive ToolsLive EventsPartner PerspectivesQ&AQuizzesSeriesSpecial ReportsSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Publication
  • Job Board
  • CME/CE
  • Partners
  • Editorial
  • Resources
  • Subscribe
  • ADHD
  • Addiction & Substance Use
    • Gambling
    • Opioid Related Disorders
    • Alcohol Abuse
    • Amphetamine Related Disorders
    • Substance Use Disorder
  • Alzheimer Disease
  • Anxiety & Stress Disorders
    • Disaster Psychiatry
    • Panic Disorder
    • Trauma And Violence
    • Traumatic Stress Disorders
  • Bipolar Disorder
    • Mania
  • COVID-19
  • Cannabis
  • Case Discussions
  • Child & Adolescent Psychiatry
  • Climate Change
  • Comorbidity
  • Compulsive Disorders
  • Cultural Psychiatry
  • Digital Therapeutics
  • Diversity, Equity, Inclusion
  • Drug Watch
  • Eating Disorders
  • Emergency Psychiatry
  • Ethics
  • Forensic Psychiatry
    • Munchausen Syndrome
    • Sexual Offenses
  • Geriatric Psychiatry
  • Integrative Psychiatry
  • Major Depressive Disorder
  • Media & Psychiatry
  • Mental Health Awareness Month
  • Mood Disorders
  • Neuropsychiatry
    • Cognitive Disorders
    • Dementia
    • Autism
  • PTSD
  • Personality Disorders
    • Compulsive Personality Disorder
    • Dependent Personality Disorder
    • Dissociative Identity Disorder
    • Histrionic Personality Disorder
    • Schizoid Personality Disorder
    • Antisocial Personality Disorder
    • Borderline Personality
  • Postpartum Depression
  • Psychedelics
  • Psychopharmacology
  • Psychosomatics
    • Delirium
    • Metabolic Disorders
    • Somatoform Disorder
  • Psychotherapy
    • Cognitive Behavioral Therapy
  • Schizophrenia/Psychosis
    • Paranoid Schizophrenia
    • Psychotic Affective Disorders
    • Schizoaffective
    • Schizophrenia Psychotic Features
    • Schizotypal Personality Disorder
    • Catatonic Schizophrenia
  • Sleep Disorders
    • Narcolepsy
    • Nocturnal Paroxysmal Dystonia
    • Sleep Deprivation
    • Sleep Wake Transition
    • Circadian Rhythm Sleep Disorders
  • Special Populations
    • Pervasive Developmental Disorder
    • LGBTQ+
    • Gender Issues
    • Military Mental Health
  • Sports Psychiatry
  • Suicide
  • Tardive Dyskinesia
  • Technology & Psychiatry
    • Artificial Intelligence
  • Transcranial Magnetic Stimulation
Spotlight -
Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|
Major Depressive Disorder
Advertisement
News|Articles|December 27, 2023

The Year in Cover Stories 2023

Author(s)Erin O'Brien

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

Advertisement

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!
Advertisement

Related Content

Advertisement

Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia

ByJessica Walters
December 27th 2025

Latest Alzheimer Disease Data: Reports from CTAD 2025

ByJessica Walters
December 25th 2025

Psychiatry and Artificial Intelligence in 2025

ByJessica Walters
December 24th 2025

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

ByJessica Walters
December 24th 2025

Cobenfy for Treatment of Schizophrenia Now Approved in China

ByJessica Walters
December 23rd 2025
Advertisement
Advertisement

Trending on Psychiatric Times

1

Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia

2

Cobenfy for Treatment of Schizophrenia Now Approved in China

3

Programs for ST-905 and ST-905 for Schizophrenia and Depression Launched by Syremis Therapeutics

4

Latest Alzheimer Disease Data: Reports from CTAD 2025

5

FDA Recommends Additional Phase 3 Trial for Brilaroxazine for Schizophrenia

  • About
  • Advertise
  • Contact Us
  • Editorial
  • Terms and Conditions
  • Privacy Policy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us